- Dec 11, 2025: Eli Lilly (LLY): experimental "triple G" delivered the best weight loss thus far in a clinical study. Retatrutide works by mimicking a trio of hormones — GLP-1, GIPR and glucagon — to curb hunger signals and improve blood sugar levels. In a Phase 3 study, patients with obesity and osteoarthritis of the knee, but not type 2 diabetes, lost up to 28.7% of their body weight after 68 weeks.
The results top the 22.5% reduction seen with Lilly's tirzepatide in a 72-week study. Tirzepatide, which sells under the brands Mounjaro and Zepbound for diabetes and weight loss, mimics GLP-1 and GIPR.
There are likely three future categories for weight-loss drugs: low weight loss, mid weight loss and "super high weight loss." Retatrutide likely fits into the last group. Tirzepatide "rules supreme" in the mid weight-loss category, with oral drugs likely to fill the low weight-loss space.
In additional secondary endpoints, retatrutide reduced known markers of cardiovascular risk, including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP), and at the highest dose lowered systolic blood pressure by 14.0 mmHg, using the efficacy estimand.4 In an additional post-hoc analysis, 14.1% of patients on retatrutide 9 mg and 12.0% patients on retatrutide 12 mg were completely free of knee pain at 68 weeks compared to 4.2% on placebo, based on the observed efficacy estimand data.
No comments:
Post a Comment